VTRSHealthcare · Drug Manufacturers - Specialty & GenericThe 12 Wall Street analysts covering Viatris, Inc. hold a median 12-month price target of $20 — +7.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 100 of 100 as at 15 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Viatris, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Quality (71): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Size (10): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on VTRS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +7.2% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Oct 2026 | UBS | Maintains | Buy | $23 → $26 |
| 23 Sept 2026 | Oppenheimer | Initiates | Outperform | — |
| 23 Sept 2026 | Oppenheimer | Initiates | Outperform | $25 |
| 16 Sept 2026 | Piper Sandler | Maintains | Neutral | $12 → $13 |
| 16 Sept 2026 | Piper Sandler | Maintains | Neutral | — |
| 9 Sept 2026 | Leerink Partners | Initiates | Outperform | $20 |
| 9 Sept 2026 | Leerink Partners | Initiates | Outperform | — |
| 8 Sept 2026 | Argus Research | Maintains | Buy | — |
| 8 Sept 2026 | Argus Research | Maintains | Buy | $15 → $20 |
| 19 May 2026 | Barclays | Maintains | Overweight | $17 → $22 |
| 19 May 2026 | Barclays | Maintains | Overweight | — |
| 8 May 2026 | JP Morgan | Maintains | Neutral | — |
| 8 May 2026 | Truist Securities | Maintains | Buy | — |
| 24 Mar 2026 | Barclays | Maintains | Overweight | — |
| 28 Jan 2026 | Piper Sandler | Maintains | Neutral | — |
| 16 Jan 2026 | Argus Research | Upgrade | Buy | — |
| 9 Dec 2025 | Barclays | Initiates | Overweight | — |
| 15 Oct 2025 | Truist Securities | Initiates | Buy | — |
| 6 June 2025 | Goldman Sachs | Initiates | Neutral | — |
| 7 Mar 2025 | Jefferies | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VTRS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 16 Oct 2026, Viatris, Inc. returned +91.0% against +16.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 3% of US stocks
Cheaper than 60% of US stocks
Cheaper than 53% of US stocks
Cheaper than 46% of US stocks
Higher than 39% of US stocks
Higher than 41% of US stocks
Higher than 47% of US stocks
Higher than 68% of US stocks
Higher than 27% of US stocks
Higher than 41% of US stocks
Higher than 63% of US stocks
Higher than 83% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Viatris, Inc. has a market value of $20.9B and an enterprise value of $33.0B.
Revenue in the twelve months to 30 June 2026: $14.7B. The latest quarter grew 4.9% year on year.
Net income over the same four quarters: −$410.7M, a −2.8% net margin.
Diluted earnings per share, trailing twelve months: $−0.36.
Free cash flow in the twelve months to 30 June 2026: $1.8B, after $376.0M of capital spending.
Viatris, Inc. spent $300.1M on share buybacks and $557.5M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 235.8×; forward P/E: 6.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.63%, paying out 960% of earnings.
Viatris, Inc. employs 30,000 people — $491K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Viatris, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Viatris announced that the FDA approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for treating presbyopia in adults. The product is also approved in the United States for pharmacologically induced mydriasis.
Why it matters — The approval adds an adult presbyopia indication to a Viatris product already approved for pharmacologically induced mydriasis.
Kahn Swick & Foti, LLC is investigating the proposed sale of Pacira BioSciences to Viatris, including the adequacy of the $36.50-per-share cash consideration and the sale process.
Why it matters — The investigation concerns the terms and process of Viatris’s proposed acquisition of Pacira.
Viatris is set to acquire Pacira for $1.65 billion in cash. The deal would add two marketed pain therapies and a clinical-stage gene therapy candidate to Viatris’ non-opioid pain portfolio.
Why it matters — The acquisition would expand Viatris’ portfolio of non-opioid pain treatments and include a clinical-stage gene therapy candidate.
The article analyzes 84 long-tenured dividend stocks for October 2026, assessing yield-based selections and free-cash-flow safety. It identifies 15 of 36 “safer” dividend stocks as meeting its IDEAL standard.
Why it matters — The excerpt does not mention Viatris, so it provides no company-specific information for VTRS watchers.
Brodsky & Smith announced an investigation into potential claims against Pacira BioSciences’ board related to its proposed sale to Viatris for $36.50 per share in cash, or an aggregate equity value of $1.65 billion. The investigation concerns the fairness of the sale process and whether the proposed price represents fair value to Pacira shareholders.
Why it matters — The investigation relates to Viatris’ proposed acquisition of Pacira and raises questions about the transaction process and consideration.
The 12 Wall Street analysts covering Viatris, Inc. have a median 12-month price target of $20, with estimates ranging from $13 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Viatris, Inc., 7 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Viatris, Inc. 100 out of 100 across roughly 4,600 US stocks as at 15 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Oct 2026, Viatris, Inc. ranks 100 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +7.2% from the last close, and Ticker Nerd's factor model ranks Viatris, Inc. 100 out of 100 as at 15 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Viatris, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VTRS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $26 over the next 12 months.
Viatris, Inc. returned +91.0% over the 12 months to 16 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Viatris Inc. is a global healthcare company focused on expanding access to a broad range of medicines across multiple therapeutic areas.
The most recent item we track (PRNewsWire, 16 Oct 2026): "Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia". Viatris announced that the FDA approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for treating presbyopia in adults. The product is also approved in the United States for pharmacologically induced mydriasis.
Viatris Inc. is a global healthcare company focused on expanding access to a broad range of medicines across multiple therapeutic areas. Its portfolio includes established prescription brands, generic and complex generic medicines, biosimilars, and over-the-counter consumer products that support treatment and disease management worldwide. Viatris serves patients and healthcare systems in developed and emerging markets through operations organized across Developed Markets, Greater China, JANZ, and Emerging Markets. The company also emphasizes reliable manufacturing, distribution, and supply continuity for essential therapies, helping connect more people to trusted medicines regardless of geography or circumstance. Headquartered in Canonsburg, Pennsylvania, Viatris operates as a diversified pharmaceutical business with a broad international footprint and a focus on scalable healthcare access.
CEO Mr. Scott Andrew Smith Ph.D. · 30,000 employees · United States · https://www.viatris.com
